Wall Street analyst estimates for Regeneron Pharmaceuticals, Inc. (REGN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-28 | $15.99 | ||
| 2026-07-30 | $14.29 | $10.16 | +40.6% |
| 2026-04-29 | $9.47 | $8.91 | +6.3% |
| 2026-01-30 | $11.44 | $10.74 | +6.5% |
| 2025-10-28 | $11.83 | $9.65 | +22.6% |
| 2025-08-01 | $12.89 | $8.43 | +52.9% |
| 2025-04-29 | $8.22 | $8.62 | -4.6% |
| 2025-02-04 | $12.07 | $11.21 | +7.7% |
Valuation Ratios
| P/E Ratio | 18.61 |
| Price / Book | 2.54 |
| EV / EBITDA | 13.82 |
| Dividend Yield | 0.47% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.86B | $5.87B | $6.71B | $6.56B | $8.50B | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| Cost of Revenue | $404.4M | $542.5M | $582.3M | $975.4M | $1.36B | $2.72B | $1.71B | $2.24B | $1.97B | $2.10B |
| Gross Profit | $4.46B | $5.33B | $6.13B | $5.58B | $7.14B | $13.35B | $10.47B | $10.87B | $12.23B | $12.24B |
| Research & Development | $1.95B | $1.93B | $2.04B | $2.24B | $2.50B | $2.62B | $3.06B | $3.99B | $5.23B | $5.85B |
| Selling, General & Admin | $1.18B | $1.32B | $1.56B | $1.34B | $1.35B | $1.82B | $2.12B | $2.54B | $2.95B | $2.70B |
| Operating Expenses | $3.13B | $3.25B | $3.59B | $3.37B | $3.56B | $4.40B | $5.08B | $6.52B | $8.24B | $8.66B |
| Operating Income | $1.33B | $2.08B | $2.53B | $2.21B | $3.58B | $8.95B | $5.39B | $4.35B | $3.99B | $3.58B |
| EBITDA | $1.44B | $2.25B | $2.73B | $2.67B | $4.10B | $9.67B | $5.26B | $4.69B | $5.32B | $5.82B |
| Interest Expense | $7.2M | $25.1M | $28.2M | $30.2M | $56.9M | $57.3M | $59.4M | $73.0M | $55.2M | $43.8M |
| Pre-tax Income | $1.33B | $2.08B | $2.55B | $2.43B | $3.81B | $9.33B | $4.86B | $4.20B | $4.78B | $5.23B |
| Income Tax | $434.3M | $880.0M | $109.1M | $313.3M | $297.2M | $1.25B | $520.4M | $245.7M | $367.3M | $725.8M |
| Net Income | $895.5M | $1.20B | $2.44B | $2.12B | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| EPS | $8.55 | $11.27 | $21.29 | $19.38 | $32.65 | $76.40 | $40.51 | $37.05 | $40.90 | $43.07 |
| EPS (Diluted) | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Shares Outstanding (Diluted) | $116.3M | $115.9M | $114.8M | $114.6M | $115.1M | $112.2M | $113.5M | $113.7M | $115.1M | $108.6M |
Price
| Price | $784.85 |
| Market Cap | $80.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALNY · ARGX · CI · COR · ELV · GMAB · IDXX
Explore sector: Healthcare · Biotechnology
More sections of REGN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks